Empagliflozin and Atrial Fibrillation Treatment
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.
Also called NCT04583813
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 400 participants
- Sponsor
- Miulli General Hospital
- Registry
-
NCT04583813
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Italy
- Registry status
- Unknown status
Technical summary
Registry record NCT04583813. Randomized; double masking; primary purpose treatment. Start 2021-09 (anticipated); primary completion 2024-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Empagliflozin and Atrial Fibrillation Treatment
- Acronym
- EMPA-AF
- Condition
- Atrial Fibrillation
- Condition
- Heart Failure
- Condition
- Obesity
- Condition
- Diabetes Mellitus
- Intervention (Drug)
- Empagliflozin
- Intervention (Other)
- Placebo
- Lead sponsor
- Miulli General Hospital
Record details
- Record id
cardio:ct-nct04583813- Content hash
f90801a5150deacfa25cb4ed98618c4af7a2c5bdf261b366792357235619b60d